BioCentury
ARTICLE | Financial News

Amgen climbs on Aranesp rumors

July 18, 2001 7:00 AM UTC

AMGN was up $4.99 to $60.05 on 15 million shares on Wednesday, as rumors circulated that the company had received FDA approval for its Aranesp darbepoietin alfa modified erythropoietin to treat anemia...